Compare EFSC & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EFSC | TLX |
|---|---|---|
| Founded | 1988 | 2015 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.2B |
| IPO Year | N/A | N/A |
| Metric | EFSC | TLX |
|---|---|---|
| Price | $53.27 | $9.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $66.00 | $21.13 |
| AVG Volume (30 Days) | 215.5K | ★ 275.4K |
| Earning Date | 04-27-2026 | 04-17-2026 |
| Dividend Yield | ★ 2.43% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.91 | N/A |
| Revenue Next Year | $3.60 | N/A |
| P/E Ratio | ★ $11.50 | $150.33 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $45.22 | $6.28 |
| 52 Week High | $62.20 | $19.93 |
| Indicator | EFSC | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 38.19 | 68.42 |
| Support Level | $51.60 | $8.85 |
| Resistance Level | $54.28 | $9.92 |
| Average True Range (ATR) | 1.16 | 0.25 |
| MACD | 0.12 | 0.11 |
| Stochastic Oscillator | 39.07 | 91.46 |
Enterprise Financial Services Corporation is a financial holding company. It offers banking and wealth management services to individuals and business customers located in Arizona, California, Florida, Kansas, Missouri, Nevada, and New Mexico, in addition to loan and deposit production offices throughout the United States. The company offers a broad range of business and personal banking services including wealth management services. Lending services include commercial and industrial, commercial real estate, real estate construction and development, residential real estate and consumer loans.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.